LYELL IMMUNOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.17 USD | -1.36% |
|
-2.69% | +11.86% |
| Mar. 04 | North American Morning Briefing : Stock Futures -2- | DJ |
| Feb. 28 | Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,861 | 865.2 | 488.6 | 553.2 | - | - |
| Enterprise Value (EV) 1 | 1,634 | 225 | -57.6 | 23.84 | -69.46 | 553.2 |
| P/E ratio | -4.21 x | -4.69 x | -2.09 x | -2.49 x | -2.37 x | -2.31 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 175 x | 10.2 x | 3,759 x | 277 x | 221 x | - |
| EV / Revenue | 153 x | 2.66 x | -443 x | 11.9 x | -27.8 x | - |
| EV / EBITDA | -8.12 x | -1.33 x | 0.25 x | -0.1 x | 0.24 x | -1.36 x |
| EV / FCF | -8.52 x | -1.16 x | 0.35 x | -0.15 x | 0.38 x | -2.5 x |
| FCF Yield | -11.7% | -86.1% | 289% | -675% | 263% | -39.9% |
| Price to Book | 2.02 x | 1.04 x | 0.75 x | 0.85 x | 0.84 x | - |
| Nbr of stocks (in thousands) | 240,471 | 249,326 | 251,869 | 254,937 | - | - |
| Reference price 2 | 7.740 | 3.470 | 1.940 | 2.170 | 2.170 | 2.170 |
| Announcement Date | 3/29/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 10.65 | 84.68 | 0.13 | 2 | 2.5 | - |
| EBITDA 1 | - | -201.2 | -169 | -226.8 | -227.1 | -285.6 | -406.2 |
| EBIT 1 | - | -214.8 | -187.1 | -247 | -239 | -275.4 | -355.9 |
| Operating Margin | - | -2,016.68% | -220.89% | -190,006.15% | -11,951.48% | -11,015.56% | - |
| Earnings before Tax (EBT) 1 | - | - | -183.1 | -234.6 | -224.7 | -259.2 | -342.6 |
| Net income 1 | -204.5 | -250.2 | -183.1 | -234.6 | -224.7 | -259.2 | -342.6 |
| Net margin | - | -2,349.47% | -216.24% | -180,486.15% | -11,233.97% | -10,368.07% | - |
| EPS 2 | - | -1.840 | -0.7400 | -0.9300 | -0.8711 | -0.9162 | -0.9377 |
| Free Cash Flow 1 | - | -191.8 | -193.8 | -166.4 | -161 | -183 | -221 |
| FCF margin | - | -1,800.5% | -228.89% | -127,984.62% | -8,050% | -7,320% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 5/12/21 | 3/29/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.755 | 2.822 | 0.553 | 35.74 | 0.003 | 48.39 | 0.065 | 0.027 | 0.025 | 0.013 | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | -60.84 | -53.94 | -54.45 | - | - | - | - |
| EBIT 1 | -49.16 | -47.54 | -68.58 | -37.26 | -66.44 | -14.78 | -62.56 | -65.9 | -59.04 | -59.51 | -59.4 | -61.05 | -59.55 | -62.02 |
| Operating Margin | -1,784.43% | -1,684.55% | -12,400.72% | -104.25% | -2,214,566.67% | -30.55% | -96,240% | -244,092.59% | -236,156% | -457,753.85% | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -68.14 | -36.32 | -70.25 | -8.397 | -66.96 | -63.89 | -50.85 | -52.93 | -50.58 | -51.9 | -52.31 | -53.21 |
| Net income 1 | - | -83.71 | -68.14 | -36.32 | -70.25 | -8.397 | -66.96 | -63.89 | -50.85 | -52.93 | -50.58 | -51.9 | -52.31 | -53.21 |
| Net margin | - | -2,966.19% | -12,322.6% | -101.63% | -2,341,800% | -17.35% | -103,013.85% | -236,629.63% | -203,412% | -407,153.85% | - | - | - | - |
| EPS 2 | -0.2000 | -0.1800 | -0.2800 | -0.1500 | -0.2800 | -0.0300 | -0.2700 | -0.2600 | -0.2000 | -0.2000 | -0.2116 | -0.2164 | -0.2166 | -0.2202 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 3/29/22 | 5/10/22 | 8/4/22 | 11/8/22 | 2/28/23 | 5/4/23 | 8/8/23 | 11/7/23 | 2/28/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 227 | 640 | 546 | 529 | 623 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -192 | -194 | -166 | -161 | -183 | -221 |
| ROE (net income / shareholders' equity) | - | -78.5% | -20.8% | -31.5% | -36.6% | -43.4% | -74.3% |
| ROA (Net income/ Total Assets) | - | -24.6% | -17.7% | -27.8% | -34.2% | -45.5% | -59.2% |
| Assets 1 | - | 1,018 | 1,032 | 843.8 | 656.1 | 569.2 | 579.1 |
| Book Value Per Share 2 | - | 3.830 | 3.340 | 2.580 | 2.560 | 2.580 | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 65.5 | 24.3 | 2.69 | 3 | 3 | 3 |
| Capex / Sales | - | 615.06% | 28.67% | 2,066.15% | 150% | 120% | - |
| Announcement Date | 5/12/21 | 3/29/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.17
USD
Average target price
6.333
USD
Spread / Average Target
+191.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.86% | 553M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- LYEL Stock
- Financials Lyell Immunopharma, Inc.
